Castle Biosciences Inc (CSTL) News

Quarterly Report (10-q)

000144736212/312023Q1false00014473622023-01-012023-03-3100014473622023-04-24xbrli:shares00014473622023-03-31iso4217:USD00014473622022-12-31iso4217:...

Current Report Filing (8-k)

0001447362FALSE00014473622023-05-032023-05-03UNITED STATESSECURITIES AND EXCHANGE COMMISSIONWashington, D.C. 20549FORM 8-KCURRENT REPORTPursuant...

Castle Biosciences Reports First Quarter 2023 Results

Q1 2023 revenue increased 57% over Q1 2022 to $42 million Q1 2023 total test reports increased 73% over Q1 2022 Reaffirming full-year 2023...

Study Demonstrates Use of DecisionDx®-Melanoma to Guide Treatment Decisions Resulted in Earlier Detection of Melanoma with Decreased Metastatic Tumor Burden Compared to Patients Without Surveillance Imaging Studies

New independent, multi-center study found that patients who received high-risk DecisionDx-Melanoma test results received routine imaging, which...

Castle Biosciences Collaborates with IMPACT Melanoma to Provide Free Sunscreen to Cyclists Participating in the Bike MS: Texas MS 150 2023 Cycling Event

Thirteen sunscreen dispensers, positioned at rest and lunch stops, will supply sunscreen to the more than 5,200 riders to protect their skin from...

DecisionDx®-Melanoma Provides Improved Risk Stratification Over American Joint Committee on Cancer (AJCC) Staging Alone in Stage I Melanoma Patients

New data shared in a poster presentation during the 19th European Association of Dermato-Oncology (EADO) Congress Castle Biosciences, Inc...

TissueCypher® Test Results Can Increase the Likelihood of Appropriate Management Decisions for Barrett’s Esophagus Patients with Low-Grade Dysplasia

Data from patient simulation study to be presented at ESGE (European Society of Gastrointestinal Endoscopy) Days 2023 Castle Biosciences, Inc...

Castle Biosciences to Release First Quarter 2023 Financial Results and Host Conference Call on Wednesday, May 3

Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that it...

Annual Report to Security Holders (ars)

Proxy Statement (definitive) (def 14a)

Table of Contents DEF 14Afalse0001447362 0001447362 2022-01-01 2022-12-31 0001447362 2021-01-01 2021-12-31...

Castle Biosciences to Present at the 22nd Annual Needham Virtual Healthcare Conference

Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that Derek...

Statement of Changes in Beneficial Ownership (4)

FORM 4 ☐ Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b...

Statement of Changes in Beneficial Ownership (4)

FORM 4 ☐ Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b...

Statement of Changes in Beneficial Ownership (4)

FORM 4 ☐ Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b...

Late-Breaking Data Presented at the 2023 AAD Annual Meeting Demonstrates Improved Accuracy of DecisionDx®-SCC in Predicting Metastatic Risk Over Traditional Staging Systems in Independent, Multi-Center Cohort Study

Study data shows consistent independent risk stratification performance of DecisionDx-SCC in a novel cohort of patients with cutaneous squamous...